183 related articles for article (PubMed ID: 38318252)
1. Prevalence of Medication Associated with QTc Prolongation Used Among Critically Ill Patients.
Al-Azayzih A; Al-Qerem W; Al-Azzam S; Muflih S; Al-Husein BA; Kharaba Z; Kanaan RJ; Rahhal D
Vasc Health Risk Manag; 2024; 20():27-37. PubMed ID: 38318252
[TBL] [Abstract][Full Text] [Related]
2. QTc Prolongation in Poison Center Exposures to CredibleMeds List of Substances with "Known Risk of Torsades de Pointes".
Ryan K; Benz P; Zosel A; Farkas A; Theobald J
Cardiovasc Toxicol; 2022 Sep; 22(9):866-877. PubMed ID: 35930218
[TBL] [Abstract][Full Text] [Related]
3. QTc Prolongation Associated With Psychiatric Medications: A Retrospective Cross-Sectional Study of Adult Inpatients.
Shao W; Ayub S; Drutel R; Heise WC; Gerkin R
J Clin Psychopharmacol; 2019; 39(1):72-77. PubMed ID: 30531476
[TBL] [Abstract][Full Text] [Related]
4. Drug-induced torsades de pointes in an underserved urban population. Methadone: is there therapeutic equipoise?
Romero J; Baldinger SH; Goodman-Meza D; Engstrom K; Valencia CR; Golive A; Medrano F; Rangasamy S; Makkiya M; Fisher JD; Gross J; Krumerman A; Kim S; Garcia MJ; Di Biase L; Ferrick KJ
J Interv Card Electrophysiol; 2016 Jan; 45(1):37-45. PubMed ID: 26589717
[TBL] [Abstract][Full Text] [Related]
5. Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongation?
Mayet S; Gossop M; Lintzeris N; Markides V; Strang J
Drug Alcohol Rev; 2011 Jul; 30(4):388-96. PubMed ID: 21355918
[TBL] [Abstract][Full Text] [Related]
6. Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly.
Vieweg WV; Wood MA; Fernandez A; Beatty-Brooks M; Hasnain M; Pandurangi AK
Drugs Aging; 2009; 26(12):997-1012. PubMed ID: 19929028
[TBL] [Abstract][Full Text] [Related]
7. Frequency, characteristics and nature of risk factors associated with use of QT interval prolonging medications and related drug-drug interactions in a cohort of psychiatry patients.
Das B; Rawat VS; Ramasubbu SK; Kumar B
Therapie; 2019 Dec; 74(6):599-609. PubMed ID: 31053339
[TBL] [Abstract][Full Text] [Related]
8. The Incidence of QT Prolongation and Torsades des Pointes in Patients Receiving Droperidol in an Urban Emergency Department.
Cole JB; Lee SC; Martel ML; Smith SW; Biros MH; Miner JR
West J Emerg Med; 2020 Jul; 21(4):728-736. PubMed ID: 32726229
[TBL] [Abstract][Full Text] [Related]
9. Risperidone, QTc interval prolongation, and torsade de pointes: a systematic review of case reports.
Vieweg WV; Hasnain M; Hancox JC; Baranchuk A; Digby GC; Kogut C; Crouse EL; Koneru JN; Deshmukh A; Pandurangi AK
Psychopharmacology (Berl); 2013 Aug; 228(4):515-24. PubMed ID: 23812796
[TBL] [Abstract][Full Text] [Related]
10. Drug-induced QT Interval Prolongation in the Intensive Care Unit.
Etchegoyen CV; Keller GA; Mrad S; Cheng S; Di Girolamo G
Curr Clin Pharmacol; 2017; 12(4):210-222. PubMed ID: 29473523
[TBL] [Abstract][Full Text] [Related]
11. Incidence of Torsade de Pointes in a tertiary hospital population.
Vandael E; Vandenberk B; Vandenberghe J; Pincé H; Willems R; Foulon V
Int J Cardiol; 2017 Sep; 243():511-515. PubMed ID: 28576628
[TBL] [Abstract][Full Text] [Related]
12. Citalopram induced torsade de pointes, a rare life threatening side effect.
Kanjanauthai S; Kanluen T; Chareonthaitawee P
Int J Cardiol; 2008 Dec; 131(1):e33-4. PubMed ID: 17919753
[TBL] [Abstract][Full Text] [Related]
13. The Association of Proton Pump Inhibitors and QT Interval Prolongation in Critically Ill Patients.
Fan W; Liu H; Shen Y; Hong K
Cardiovasc Drugs Ther; 2024 Jun; 38(3):517-525. PubMed ID: 36625987
[TBL] [Abstract][Full Text] [Related]
14. Acquired long QT syndrome from stress cardiomyopathy is associated with ventricular arrhythmias and torsades de pointes.
Madias C; Fitzgibbons TP; Alsheikh-Ali AA; Bouchard JL; Kalsmith B; Garlitski AC; Tighe DA; Estes NA; Aurigemma GP; Link MS
Heart Rhythm; 2011 Apr; 8(4):555-61. PubMed ID: 21146632
[TBL] [Abstract][Full Text] [Related]
15. Assessment of drug-induced torsade de pointes risk for hospitalized high-risk patients receiving QT-prolonging agents.
Jardin CG; Putney D; Michaud S
Ann Pharmacother; 2014 Feb; 48(2):196-202. PubMed ID: 24301687
[TBL] [Abstract][Full Text] [Related]
16. The morphology of the QT interval predicts torsade de pointes during acquired bradyarrhythmias.
Topilski I; Rogowski O; Rosso R; Justo D; Copperman Y; Glikson M; Belhassen B; Hochenberg M; Viskin S
J Am Coll Cardiol; 2007 Jan; 49(3):320-8. PubMed ID: 17239713
[TBL] [Abstract][Full Text] [Related]
17. QTc prolongation, torsades de pointes, and psychotropic medications.
Beach SR; Celano CM; Noseworthy PA; Januzzi JL; Huffman JC
Psychosomatics; 2013; 54(1):1-13. PubMed ID: 23295003
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of QT interval prolongation in patients admitted to cardiac care units and frequency of subsequent administration of QT interval-prolonging drugs: a prospective, observational study in a large urban academic medical center in the US.
Tisdale JE; Wroblewski HA; Overholser BR; Kingery JR; Trujillo TN; Kovacs RJ
Drug Saf; 2012 Jun; 35(6):459-70. PubMed ID: 22612851
[TBL] [Abstract][Full Text] [Related]
19. Risk management of QTc-prolongation in patients receiving haloperidol: an epidemiological study in a University hospital in Belgium.
Vandael E; Vandenberk B; Vandenberghe J; Spriet I; Willems R; Foulon V
Int J Clin Pharm; 2016 Apr; 38(2):310-20. PubMed ID: 26749342
[TBL] [Abstract][Full Text] [Related]
20. Predictive Validity of a QT
Su K; McGloin R; Gellatly RM
Pharmacotherapy; 2020 Jun; 40(6):492-499. PubMed ID: 32259316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]